SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic, Inc. was founded in 1999 and is headquartered in Boulder, Colorado.
Latest funding size
Time since last funding
|iCarbonX, Nan Fung Life Sciences, Visium Healthcare Partners, Quest Diagnostics, Otsuka Pharmaceutical, ProQuest Investments, Madryn Asset Management|